The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease

Keyphrases

• Respiratory Allergy 100%
• House Dust Mite 100%
• SLIT-tablet 100%
• Asthma 46%
• Adverse Events 30%
• Treatment-related Adverse Events 23%
• Allergic Rhinitis 23%
• Safety Data 15%
• Allergic Asthma 15%
• Denmark 7%
• Moderate to Severe 7%
• Clinical Effect 7%
• Placebo 7%
• Randomized Placebo-controlled Trial 7%
• Pharmacotherapy 7%
• Active Treatment 7%
• Treatment Group 7%
• Tolerability 7%
• Subgroup Analysis 7%
• Serious Adverse Events 7%
• Safety Profile 7%
• Inhaled Corticosteroids 7%
• Allergy 7%
• Group 12 7%
• Adult Population 7%
• Uncontrolled Asthma 7%
• Systemic Allergic Reaction 7%
• Partly Controlled Asthma 7%
• Pooled Safety 7%
• Controlled Asthma 7%
• Local Allergic Reaction 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Disease 100%
• Tablet 100%
• Dermatophagoides 100%
• Adverse Event 61%
• Asthma 46%
• Allergic Rhinitis 23%
• Placebo 15%
• Allergic Reaction 15%
• Allergic Asthma 15%
• Asthmatic State 15%
• Controlled Clinical Trial 7%
• Pharmacotherapy 7%
• Tolerability 7%
• Respiratory Tract Allergy 7%

Immunology and Microbiology

• Dermatophagoides 100%
• Asthma 46%
• Allergic Rhinitis 23%
• Allergic Asthma 15%
• Hypersensitive Response 15%
• Asthmatic State 15%
• Respiratory Tract Allergy 7%